Astria Therapeutics, Inc. is a Pharmaceuticals company based in the United States of America. With a Risk Rating Score of 28.3, the company is considered to be at a Medium Risk. Astria Therapeutics focuses on developing life-changing therapies for rare allergic and immunological diseases. Their main ESG initiative includes the development of a monoclonal antibody inhibitor for hereditary angioedema and an antagonist for atopic dermatitis.